Buccal Films, Sublingual Films, and Orodispersible Films: What Is the Difference?

Buccal films, sublingual films, and orodispersible films differ mainly in intended placement, residence behavior, and delivery pathway. Buccal films are generally designed for contact with the inner cheek and may use mucoadhesion to extend residence; sublingual films are placed beneath the tongue where a relatively permeable mucosa can support rapid absorption of suitable compounds; orodispersible films are primarily designed to disperse rapidly in the mouth, after which much of the released material may be swallowed. For peptide delivery, these distinctions can determine whether the key research question is mucosal permeation, prolonged local contact, or gastrointestinal exposure after dispersion.

Separating these dosage forms is essential to Oromucosal Peptide Film Research. All three may look like small flexible strips, but their design targets can differ substantially, and none of the names alone proves that an incorporated peptide reaches systemic circulation intact.

Dosage-form research notice for Buccal Films, Sublingual Films, and Orodispersible Films: InStrips materials are intended for analytical study of peptide-film placement, mucoadhesion, dispersion, release, and mucosal-delivery variables. Describing the differences among these film types does not mean any research material is intended to diagnose, treat, cure, or prevent a disease, injury, deficiency, digestive or absorption disorder, or other medical condition.

Buccal Films Are Designed Around the Inner Cheek

The buccal mucosa lines the inside of the cheeks.

A buccal film is generally placed directly against this surface.

Buccal Delivery Often Prioritizes Contact Time

A formulation may contain mucoadhesive polymers intended to keep it attached rather than allowing immediate dispersion into saliva.

Longer residence can increase the period during which released material remains near the mucosa.

Buccal Mucosa Is Relatively Robust

Compared with the sublingual region, buccal epithelium is generally:

• thicker
• somewhat less permeable
• well suited to sustained contact

This Can Favor Longer Delivery Windows

The cheek provides a practical surface for films intended to remain in place for minutes or longer.

That does not mean every active compound will cross the tissue efficiently.

A Buccal Film Can Be Single Layered

In a simple design, the active-containing matrix may contact both:

• mucosa
• saliva

Material can therefore release in more than one direction.

A Bilayer Buccal Film Can Create Directionality

An impermeable or slowly dissolving backing layer can reduce release toward the oral cavity.

The active-containing layer is positioned against mucosa.

Directional Release Can Reduce Salivary Loss

If less peptide enters bulk saliva, a larger fraction can theoretically remain concentrated near the tissue surface.

Whether that increases actual peptide permeation must still be measured.

Mucoadhesion Is Particularly Relevant to Buccal Design

Common research questions include:

• How strongly does the film adhere?
• How long does it remain attached?
• How much does it swell?
• Does movement dislodge it?
• Does saliva weaken adhesion?

Very Strong Adhesion Is Not Automatically Better

A film also needs appropriate:

• comfort
• flexibility
• removal or dissolution behavior

Formulation design involves tradeoffs.

Sublingual Films Are Placed Beneath the Tongue

The sublingual mucosa occupies the floor of the mouth underneath the tongue.

It has different anatomical characteristics from the cheek.

The Sublingual Mucosa Is Generally More Permeable

Its relatively thin epithelium and rich blood supply can support rapid uptake of suitable small molecules.

This Is Why Sublingual Administration Is Associated With Rapid Onset

For compounds capable of crossing the tissue efficiently, absorption can occur without requiring passage through the gastrointestinal tract first.

Peptides Do Not Automatically Behave Like Small Sublingual Drugs

A peptide can remain limited by:

• molecular size
• charge
• hydrogen bonding
• enzymatic degradation

even when placed against a more permeable mucosal region.

Sublingual Placement Also Has Practical Limitations

The area is exposed to:

• continuous saliva
• tongue movement
• swallowing
• a relatively confined placement space

A Film Can Move Away From Its Intended Site

If a sublingual formulation disperses quickly or is moved by the tongue, its actual residence pattern may differ from its nominal placement.

Placement Verification Can Matter in Research

Human formulation studies may need standardized instructions about:

• film position
• movement
• swallowing
• food or fluid timing

Orodispersible Films Are Defined More by Rapid Dispersion

An orodispersible film is placed in the mouth and designed to disperse rapidly upon contact with saliva.

It need not remain attached to one mucosal site for a prolonged period.

Orodispersible Does Not Mean Buccal

A rapidly dispersing film placed on the tongue and swallowed differs fundamentally from a mucoadhesive film attached to the cheek.

Orodispersible Does Not Necessarily Mean Sublingual Either

The dosage form can disperse in the oral cavity without being specifically designed for placement under the tongue.

The Released Active May Be Swallowed

After rapid dispersion:

1. the film hydrates
2. the matrix breaks down
3. active material enters saliva
4. saliva is swallowed

This Can Make the Gastrointestinal Tract the Main Absorption Site

For many conventional orally active small molecules, that can be entirely appropriate.

For Peptides, Swallowing Creates Additional Barriers

A swallowed peptide may encounter:

• gastric acidity
• pepsin
• intestinal proteases
• poor intestinal epithelial permeability

A Peptide ODF Therefore Needs a Defined Delivery Objective

Researchers should ask whether the formulation is intended primarily to:

• improve convenience before swallowing
• promote some oral-mucosal exposure
• achieve predominantly transmucosal systemic delivery

The Three Film Types Can Be Compared by Residence

A simplified conceptual comparison is:

• buccal: often longer residence against cheek
• sublingual: site-specific placement beneath tongue, often targeting relatively rapid absorption
• orodispersible: rapid breakup in saliva

Actual formulations can depart from these general patterns.

Film Names Should Reflect Formulation Behavior

A rapidly disintegrating buccal film and a prolonged-release buccal film are both placed against the cheek but can behave very differently.

Likewise, Not Every Sublingual Film Is Identical

Designs can vary in:

• adhesion
• dissolution time
• drug loading
• polymer system
• permeation strategy

Mucoadhesion Is Not Required for Every Orodispersible Film

An ODF may be intended to break down too quickly for prolonged adhesion to be useful.

Disintegration Time Can Therefore Help Clarify Identity

A film that disperses rapidly within saliva likely presents a different delivery profile from one engineered to remain intact against the cheek.

But Disintegration Time Alone Is Not Enough

Two films with similar disintegration times can release different percentages of peptide or differ substantially in mucosal contact.

Film Thickness Can Shift Performance

A thicker film may:

• carry more active material
• hydrate more slowly
• remain mechanically stronger
• feel more noticeable in the mouth

Surface Area Also Matters

A larger film can contact more mucosa but may be less comfortable or harder to keep in place.

Peptide Concentration at the Tissue Surface Matters More Than Total Dose Alone

Mucosal permeation is driven partly by concentration gradients.

A film that concentrates peptide within a small hydrated interface may behave differently from one that rapidly dilutes it into saliva.

Backing Layers Can Influence This Gradient

By limiting outward loss, a backing layer can increase the fraction of released material available at the tissue-facing surface.

Permeation Enhancers Are a Separate Formulation Variable

Researchers sometimes investigate excipients intended to alter epithelial barrier properties.

These can act through mechanisms involving:

• membrane fluidity
• tight-junction behavior
• mucus interaction

Greater Permeation Is Not Automatically Better

Barrier modification also raises questions about:

• local irritation
• reversibility
• tissue integrity
• non-specific permeability

Enhancer Evidence Is Formulation Specific

An enhancer shown to increase movement of one molecule through one tissue model cannot automatically establish comparable delivery of another peptide.

Enzyme Inhibitors Address a Different Barrier

A peptide may be degraded at the mucosal surface before crossing the epithelium.

Protease-modifying formulation strategies seek to protect the molecular species during the exposure window.

Stability and Permeation Must Both Succeed

A highly permeable peptide that degrades immediately may show little intact exposure.

A perfectly stable peptide that cannot cross the epithelium may also show little systemic exposure.

The Best Placement Site Is Peptide Dependent

No universal rule makes:

• buccal
• sublingual
• orodispersible

the best formulation for every peptide.

Model Selection Matters in Permeation Research

Studies may use:

• porcine buccal tissue
• other animal mucosa
• cell-culture barrier models
• artificial membranes

These Models Are Not Interchangeable

Different tissues can vary in:

• epithelial thickness
• lipid content
• enzyme activity
• barrier resistance

Human Exposure Requires Later Confirmation

Even a strong ex vivo permeability result does not establish human systemic bioavailability.

The Intact Peptide Should Be Measured Where Possible

For peptide delivery, an assay should ideally distinguish parent peptide from:

• metabolites
• fragments
• related immunoreactive species

A Film Cannot Be Classified by Marketing Language Alone

Words such as:

• rapid
• fast melt
• buccal
• sublingual
• transmucosal

should correspond to measurable formulation characteristics.

A Better Research Description Uses Multiple Attributes

For example:

mucoadhesive bilayer buccal film intended for directional peptide release

provides much more information than:

oral peptide strip

The Next Question Is Whether Material Actually Crosses the Mucosa

Dosage-form identity and placement are only the starting points.

The broader meaning of movement through oral mucosa is examined in What Does Transmucosal Peptide Delivery Mean?.

Reading an Oromucosal Delivery Review

The open-access review Transmucosal Drug Administration as an Alternative Route distinguishes mucoadhesive buccal films from rapidly dispersing films and describes how buccal-film architecture can use a drug-containing adhesive layer and a backing layer to support prolonged or directional mucosal exposure.

These dosage-form principles help separate buccal, sublingual, and orodispersible designs. They should not be taken as proof that an incorporated peptide achieves systemic absorption without peptide-specific stability, permeability, and pharmacokinetic evidence.

Final Perspective

Buccal, sublingual, and orodispersible films may share a thin flexible format, but they are designed around different locations and performance characteristics.

Buccal films often emphasize mucoadhesion and sustained cheek contact, sublingual films use the region beneath the tongue and may target relatively rapid uptake, while orodispersible films primarily emphasize rapid dispersion in saliva and can lead largely to swallowing.

For peptide research, the exact site, residence time, release pattern, enzymatic stability, and measured mucosal permeation matter more than the general appearance of the strip. Film identity should therefore be established from formulation design and demonstrated behavior rather than broad oral-film terminology.